UMRX vs. KNSA, RCUS, OCUL, MRVI, ARVN, HROW, PRAX, CALT, DAWN, and ANIP
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Maravai LifeSciences (MRVI), Arvinas (ARVN), Harrow (HROW), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), and ANI Pharmaceuticals (ANIP). These companies are all part of the "medical" sector.
Cogent Biosciences vs.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Comparatively, 31.5% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Kiniksa Pharmaceuticals currently has a consensus price target of $36.60, indicating a potential upside of 85.13%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Cogent Biosciences.
Kiniksa Pharmaceuticals has higher revenue and earnings than Cogent Biosciences. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.
Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Cogent Biosciences' net margin of -96.84%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Cogent Biosciences' return on equity.
Cogent Biosciences received 15 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 68.38% of users gave Cogent Biosciences an outperform vote while only 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote.
Kiniksa Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500.
In the previous week, Kiniksa Pharmaceuticals had 7 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Kiniksa Pharmaceuticals and 0 mentions for Cogent Biosciences. Kiniksa Pharmaceuticals' average media sentiment score of 0.76 beat Cogent Biosciences' score of 0.00 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media.
Summary
Kiniksa Pharmaceuticals beats Cogent Biosciences on 13 of the 18 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:UMRX) was last updated on 1/24/2025 by MarketBeat.com Staff
